Adults with type 2 diabetes and obesity who took weekly semaglutide injections for 12 weeks lost an average of 5.6 kg, dropping from 88.5 kg to 82.9 kg. However, because the study did not include a control group, this weight loss cannot be confidently attributed to the medication alone.
See the scientific wording
In adults aged 25–60 years with type 2 diabetes and obesity (BMI ≥27 kg/m²), 12 weeks of once-weekly subcutaneous semaglutide is associated with a mean weight reduction from 88.5 kg to 82.9 kg, a decrease of 5.6 kg.
Correlational — new studies may shift this
ObservationalOne low-scoring study links this claim to the outcome, but causation is not established.
What the research says
1 study reviewedSupporting (1)
Cohort StudyHuman
The study looked at people with type 2 diabetes and obesity who took semaglutide injections for 12 weeks and found they lost an average of 5.6 kg, which matches what the claim says. However, because the study didn't compare them to people not taking the drug, we can't be sure the drug caused the loss, just like the claim says.
Contradicting (0)
No contradicting studies found yet
That doesn't mean it's settled — it just means no study has tested the opposite.
Quality-weighted scoring: we follow the GRADE framework — each study is rated High, Moderate, Low, or Very Low based on study design, methodology rigor, and risk of bias. A single high-quality RCT can outweigh several weaker observational studies.
Scores reflect study quality, not just count.
Semaglutide makes your brain signal that you are full. This reduces how much you eat. Eating less for many weeks leads to weight loss.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting study
How Fit Body Science checks a claim
- 1
We isolate the claim
Health advice from videos, articles and studies is broken down into single, testable claims.
- 2
We find the research
Each claim is matched against peer-reviewed studies, with every source cited by DOI.
- 3
We grade the evidence
Studies are scored on methodology, statistical rigor, transparency and publication quality.
The fitness and health internet is full of confident claims. We check them against real research.
Every claim on this site is traced back to peer-reviewed studies, scored on methodology and reporting quality, and given a verdict you can audit yourself — sources, DOIs and all.
- Full evidence breakdown and mechanism chains
- Ask our AI anything about a claim or its studies
- Get notified when new research changes a verdict
Adults with type 2 diabetes and obesity who took weekly semaglutide injections for 12 weeks lost an average of 5.6 kg, dropping from 88.5 kg to 82.9 kg. However, because the study did not include a control group, this weight loss cannot be confidently attributed to the medication alone.
Mechanism
1 studyThe studies did not examine how semaglutide causes weight loss. But based on known science, semaglutide makes you feel full, so you eat less and lose weight over time.
Semaglutide makes your brain signal that you are full. This reduces how much you eat. Eating less for many weeks leads to weight loss.
Semaglutide binds to and activates GLP-1 receptors in the hypothalamus.
Activation of GLP-1 receptors in the hypothalamus increases satiety signaling and reduces appetite.
Reduced appetite decreases caloric intake.
Sustained caloric deficit forces the body to use stored fat for energy, resulting in weight loss.
Evidence from Studies
Supporting (1)
Community contributions welcome
The study looked at people with type 2 diabetes and obesity who took semaglutide injections for 12 weeks and found they lost an average of 5.6 kg, which matches what the claim says. However, because the study didn't compare them to people not taking the drug, we can't be sure the drug caused the loss, just like the claim says.
Contradicting (0)
Community contributions welcome
Score Breakdown
No multi-axis breakdown available yet. The overall Pro / Against score above is the best signal.
- No clinical evidence is available; the score reflects mechanistic plausibility only.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
Systematic Review and Meta-Analysis of RCTs on Semaglutide for Weight Loss in Type 2 Diabetes and Obesity
Systematic review and meta-analysis of double-blind, placebo-controlled RCTs with at least 12 weeks of once-weekly subcutaneous semaglutide (any dose) in adults aged 25-60 with T2D and BMI ≥27, reporting weight change as primary outcome.
Double-Blind, Placebo-Controlled Randomized Trial of Semaglutide for 12 Weeks in Adults with T2D and Obesity
Double-blind, placebo-controlled, parallel-group RCT randomizing adults 25-60 with T2D and BMI ≥27 to once-weekly subcutaneous semaglutide (starting 0.25 mg, titrated to 1.0 mg) or placebo for 12 weeks. Primary outcome: absolute and relative change in body weight. Secondary: HbA1c, waist circumference.
Prospective Cohort Study of Semaglutide Versus Other GLP-1 Agonists for Weight Loss in T2D Patients
Prospective cohort study following adults 25-60 with T2D and BMI ≥27 starting semaglutide or another GLP-1 agonist (e.g., liraglutide) for at least 12 weeks, measuring weight change and adjusting for confounders.
Case-Control Study of Semaglutide Exposure and Weight Loss in T2D and Obesity
Retrospective case-control study: cases are adults 25-60 with T2D and BMI ≥27 who achieved ≥5% weight loss over 12 weeks; controls are matched patients who did not. Exposure is semaglutide prescription. Odds ratios calculated.